UPDATE: Seer CEO Improves Takeover Bid
Summary
Seer’s CEO improved his takeover bid for the proteomics company by keeping the same cash price and increasing the contingent value rights. The revised offer now includes larger payouts tied to future revenue milestones and a potential sale or strategic disposition of Seer or its core assets. Shareholders Bradley Radoff and Michael Torok had just raised their own competing bid, adding pressure to the process. Seer’s board has already rejected all takeover offers so far. The company’s shares rose in after-hours trading following the news.
AskAI Classifications
Sectors
Life Sciences and Pharmaceutical
Life Sciences Management
Functions
Business Intelligence and Analytics
BI Analytics
Linked Companies
Seer
$10M to $25M